Portal de Periódicos da CAPES

Current role of thalidomide in cancer treatment

2000; Lippincott Williams & Wilkins; Volume: 12; Issue: 6 Linguagem: Inglês

10.1097/00001622-200011000-00009

1531-703X

Deborah A. Thomas, Hagop M. Kantarjian,

Protein Degradation and Inhibitors

Thalidomide (Thalidomid, Celgene, Warren, NJ) is a putative anti-angiogenesis and immunomodulatory agent that has demonstrated activity in various dermatologic and rheumatologic conditions in addition to Crohn's disease. The biologic effects of thalidomide and the clinical trials conducted in solid tumors, hematologic malignancies, chronic graft-versus-host disease (GVHD), and cancer-related cachexia are reviewed. A summary of the preliminary results of ongoing clinical trials is presented, and the future directions of thalidomide research in the oncology are discussed.